Introduction
Diabetes affects one-third of those aged 65 and older [1 ] and poses a considerable burden on healthcare resources. Observational and population studies on patients with type 1 and type 2 diabetes have shown an increased fracture risk in this population [2] . However, this association is not widely recognized or addressed by those caring for diabetic patients. In this review, we aim to discuss the evidence supporting the association between diabetes and fractures and review potential underlying mechanisms leading to this association.
Fracture risk
The frequency, fracture risks, and type of fractures affecting patients with type 1 and type 2 diabetes are somewhat different. We, therefore, discuss each type separately and focus on studies that distinguish their analysis between type 1 and type 2 diabetes.
Type 2 diabetes
The data on fracture risk in type 2 diabetes are not entirely consistent. Several cohort studies [3] [4] [5] [6] [7] [8] [9] [10] and a casecontrol study [11] have found an increased fracture risk in type 2 diabetes compared with the general population (see Table 1 ) [11,12,13 ,14,15] , whereas, a few studies report a decreased [16, 12] or similar fracture [13 ,14] risk in type 2 diabetes compared with the general population.
Most studies that report a positive association have limited their analysis and have found that patients with type 2 diabetes have a higher risk of hip fractures. However, studies that evaluated all types of fractures [5, 8, 11] still found hip fractures to contribute the most to the fracture risk seen in type 2 diabetes. Wrist [9] and foot [5, 10] fractures also appear to be increased in type 2 diabetes but only in patients who are on treatment with either oral antidiabetic agents (OADs) [9] or insulin [5, 10] . The risk for vertebral fractures is similar to that seen in nondiabetic individuals [6, 10, 11] . The risk of hip fractures appears to be slightly higher in men compared with women with type 2 diabetes [2, 17] and slightly higher in black compared with white women with type 2 diabetes [10] . In a large prospective study of nurses aged 34-59 years [3] , the incidence of hip fractures in women with type 2 diabetes is reported at 153 per 100 000 patients compared with 63 per 100 000. The incidence increases to 209 per 100 000 for the type 2 diabetic women treated with insulin.
A few studies have reported a similar or lower fracture risk in type 2 diabetes compared with the general population (see Table 1 ) [16,12,13 ,15] . Of these, two [13 ,14] showed no difference in fracture risk and both only adjusted for age. One was a small cross-sectional study [13 ] and the other [14] , when further adjusting for calcaneal stiffness, actually found a significantly increased risk of hip fractures in type 2 diabetic patients compared with nondiabetic controls.
Of those studies that reported a lower fracture risk in type 2 diabetes compared with the general population, two of them were unable to show this decrease to reach statistical significance, either on initial report [15] or when reanalyzed in a meta-analysis [2, 16] . The third study [12] included a large percentage (42%) of diet-controlled diabetic patients. Interestingly, of the positive studies, those that showed only a minimal increase in fracture risk involved diet-controlled [4] or early onset type 2 diabetic patients [8] . Perhaps, early in the course of diabetes, a higher bone mineral density (BMD) [5, 12, 18, 19] protects from fractures. However, as the diabetes progresses, certain factors such as hyperglycemia [9, 19] may impair bone quality, and this, then, overcomes the protective effects of a higher BMD and results in a higher risk of fractures. This hypothesis is supported by a study done by de Liefde et al.
[9] that showed a higher BMD in patients with impaired glucose tolerance, who also had a lower fracture risk hazard ratio 0.8 (0.63-1.00), whereas treated type 2 diabetic patients had a higher fracture risk hazard ratio 1.69 (1.16-2.46), despite an equally high BMD.
Finally, a recent meta-analysis [2] of 12 positive and negative studies [4] [5] [6] [7] 11, 16, 15, [20] [21] [22] [23] found that the overall relative risk (RR) of hip fractures in type 2 diabetic patients significantly increased with a RR of 1.7 (1.3-2.2). The association became stronger when examining the four cohorts with more than 10 years of follow-up [RR 2.7 (1.7-4.4)]. Foot fractures were the only other type of fracture found to be increased in type 2 diabetic patients in this meta-analysis [2] .
Type 1 diabetes
The risk of fractures is significantly greater in type 1 diabetes when compared with the general population as well as with patients with type 2 diabetes [3] . The evidence supporting a higher fracture risk in type 1 diabetes comes mostly from the same studies comparing fracture risk in type 2 diabetes with the general population, but the results for type 1 are more consistent (see Table 2 ) [7, 11, 24, 25] . Studies of type 1 diabetes have focused mostly on hip fractures and have found a higher risk of hip fractures in type 1 diabetes with a range of RR from 1.7 to 12.3 [2] . However, fracture risk was also found to be moderately increased at the spine and proximal humerus [11, 24] .
The risk appears to be similar between men and women with type 1 diabetes, although due to a smaller number of studies examining this relationship no definite conclusions can be drawn. A recent meta-analysis of five cohort studies showed an overall RR of 8.9 [confidence interval (CI) 7.1-11.2] for hip fractures in type 1 diabetic patients [2] . The incidence of hip fractures in the Nurses Health study was reported as 383 per 100 000 over a follow-up period of 2.2 million person years [3] . This is a six-fold increase from the overall incidence of hip fractures in this population, reported at 63 per 100 000, and a 2.5-fold increase from the incidence of hip fractures in type 2 diabetic patients in this population.
Pathogenesis underlying increased fracture risk in diabetes
BMD is increased in type 2 diabetes [5,6,12,13 ,19,26] even after adjustment for obesity, which is known to increase BMD [12] . A recent meta-analysis found BMD to be increased at both the spine and hip, and yet type 2 diabetic patients, especially those with longer duration of diabetes, are not protected from fractures [19] . Unlike type 2 diabetes, type 1 diabetes is associated with decreased BMD [19] . However, lower BMD alone is unable to explain the magnitude of fracture risk seen in type 1 diabetic patients [19] . Therefore, impaired bone quality rather than impaired bone density appears to be the main contributor to the higher fracture risk seen in either type of diabetes [27] . Additional factors mediating the increased fracture risks in diabetic patients are peripheral and autonomic neuropathy, recurrent hypoglycemic events, vitamin D deficiency, and thiazolidinedione therapy.
Impaired bone quality
Longstanding or poorly controlled diabetes may offset the beneficial effects of higher BMD via glycation of bone proteins and cells. Advanced glycation end products (AGEs) may adversely affect collagen, osteocytes, and multipotent bone marrow stem cells [28] [29] [30] [31] . The ability of multipotent bone marrow stem cells to proliferate or differentiate into bone or adipose tissue is decreased in the presence of AGEs in in-vitro studies [31] . Osteoclastinduced bone resorption is enhanced by AGEs in mouse models [32] and the addition of AGE to osteoblast-like cells significantly impairs their ability to produce collagen [30] . Glycated collagen in turn may be able to inhibit expression of osteoblasts [30] or become stiff and resistant to proteolytic degradation, necessary for bone turnover [33] . Rodent studies have shown impaired biomechanical properties and decreased bone formation in hyperglycemic rats. These findings were significantly attenuated when hyperglycemia was controlled [34] . Pentosidine, a crosslink structure between lysine and arginine residues, is a major AGE. A recent analysis of the Health ABC study participants [35 ] showed a significant association between urinary pentosidine levels and clinical fractures in elderly diabetic patients but not in those without diabetes. This finding supports the role of AGEs in impairing bone quality.
Few studies have looked at the association between HbA1c and fractures. Elevated HbA1c has been associated with decreased markers of bone turnover, serum osteocalcin and C-terminal telopeptide (b-CTX), in elderly nursing home patients with type 2 diabetes [14] . Another study showed that having both a higher BMI (>24) and HbA1c (>9%) was associated with a greater risk of multiple vertebral fractures on spine radiographs [odds ratio (OR) 5.4 CI 1.2-26.1] [36 ]. Other studies have shown a lower incidence of fractures in diabetic patients with a higher HbA1c. In a study of type 2 diabetic women aged 50-74 years, 26% of those with a hip fracture had an HbA1c more than 9% as compared with 50% of those who did not have a hip fracture [7] . It needs to be noted, however, that the HbA1c in this population was determined at baseline, that is, 9 years prior to their hip fracture and thus may not be reflective of their glycemic control during the follow-up period. A longer duration of diabetes is associated with a greater fracture risk in most [3] [4] [5] 9, 17] but not all [8, 11] studies on type 2 diabetic patients. The greater risk of fractures reported in patients with advanced diabetes may be due to the prolonged exposure to hyperglycemia and to the detrimental effects of AGEs on bone. The duration after which studies find an escalation in fracture risk is approximately 12-14 years after the diagnosis of diabetes [2, 4] .
In addition to the effect of hyperglycemia on bone quality, bone mineralization may be altered in diabetes due to impaired vitamin D and calcium metabolism [37, 38] . Diabetic patients are more likely to be vitamin D-deficient compared with the general population [39 ,40] . Vitamin D deficiency may be greater in type 2 diabetic patients compared with type 1 diabetic patients, even after adjusting for obesity, which is known to contribute to a higher distribution volume of this fatsoluble vitamin [41] . Hyperglycemia has been shown to 442 Parathyroids, bone and mineral metabolism impair renal calcium absorption [42] and this finding is corrected when hyperglycemia is controlled [43] . Finally, the development of renal insufficiency with its associated secondary or tertiary hyperparathyroidism and impaired vitamin D metabolism may further contribute to impaired bone quality in diabetes.
Falls
Diabetes is associated with a higher risk of falls [44, 45 ] . Diabetic neuropathy and neuromuscular impairment have been shown to be a major risk factor for falls [45 ,46] . Furthermore, diabetic neuropathy may lead to falls that are more severe and falls that are sideways, as opposed to forward or backward. Both of these fall characteristics have been associated with a greater risk of fractures [47, 48] . This is supported by findings linking diabetic neuropathy with calcaneal and metatarsal fractures [49, 50] .
A higher risk of falls has also been seen in diabetes of longer duration, and as discussed above, longer duration of diabetes is also associated with a greater fracture risk [2] . Higher rates of diabetes-related complications such as neuropathy, impaired vision due to retinopathy or cataracts [22, 45 ] , stroke [17, 51] , and impaired renal function [45 ] , more prevalent in advanced diabetes may underlie the higher risk of falls and fractures in this population.
Diabetic patients are also more likely to be on medications that increase fall risk. A large retrospective study of older diabetic patients (>66-year-old) found that male and female patients with diabetes not only had a higher risk of hip fractures, but also, when compared with agematched controls, they were more likely to be on medications that increased fall risk (59 vs. 47%, P < 0.001). These medications include sedatives, opiates, antiepileptics, and antiparkinsonian agents [17] .
Severe hypoglycemia may be another contributor to fall risk. Intensive glycemic control (HbA1c<6%) has been associated with an increased risk of falls but only in the diabetic patients treated with insulin (OR 4.36, CI 1.3-14.5) not in those treated with oral agents [45 ] . Some [4,5,8,17,20,] but not all [6, 7] studies have shown an increased risk of fracture with insulin treatment. The higher fracture risk associated with insulin use remains unchanged even when adjusted for duration of diabetes [5, 17] . A possible explanation for this finding may be an increased frequency of severe hypoglycemic events in insulin-treated diabetic patients. This may be one reason for why type 1 diabetic patients have a greater risk of fractures compared with type 2 diabetic patients. Other potential contributors to the observed difference in fracture risk between type 1 and type 2 diabetes may be lower BMI, longer duration of disease, higher rates of diabetic retinopathy resulting in impaired vision [52] , and a higher incidence of associated autoimmune diseases such as celiac disease [53] potentially predisposing type 1 diabetic patients to calcium malabsorption.
Thiazolidinediones
Recent studies have suggested an association between thiazolidinedione treatment and an increased risk of bone fractures in patients with type 2 diabetes [54,55 ,56 ] , as well as in patients with prediabetes [57] and older women with diabetes [58] . Fractures associated with thiazolidinediones were first reported in 2006, as an adverse outcome in the analysis from a Diabetes Outcome Progression trial (ADOPT), a large, double-blind randomized controlled study comparing the glycemic durability in patients with type 2 diabetes receiving monotherapy with rosiglitazone, metformin, or glyburide [59] . This study showed an increased number of fractures in women treated with rosiglitazone but not in men. There was an increased rate of fractures in the hand, humerus, and foot in these women but not in the hip [59] . The cumulative incidence of fractures was 15.1% after 5 years of rosiglitazone treatment as compared with 7.3 and 7.7% for metformin and glyburide treatment, respectively. The average age of patients was 56.3 AE 10.0, which was no different from the other treatment groups. However, the increase in fractures was also seen in younger, premenopausal participants of this study [60] . Similar findings regarding fractures have also been reported with pioglitazone use in postmenopausal diabetic women [61] . A recent case-control analysis of the UK General Practice Research Database confirmed the association of thiazolidinedione use with incident fractures (OR 2.43) [62] . Fractures were mainly reported in the hips and wrist and, unlike prior studies, the association of fractures with thiazolidinediones (TZDs) was found to be independent of age or sex. The association of fractures with TZD use in men has been further confirmed by a cross-sectional study of 43 men with type 2 diabetes. This study revealed a higher rate of radiographically confirmed vertebral fractures in those on metformin with rosiglitazone compared with those on metformin alone (66.7 vs. 27.3% P ¼ 0.01) [56 ] . These findings remained true even after adjustment for BMD and age. Based on invitro studies and animal models, TZDs seem to act on pluripotent mesenchymal bone marrow stromal cells to cause an increase in adipocyte precursors at the expense of osteoblast precursors. These changes shift the balance of osteoblast and adipocyte precursors leading to increased fat accumulation, bone loss, and ultimately increased fracture risk [63, 64] . However, studies on humans have not been done and other potential mechanisms, including an indirect negative effect on osteoblasts via enhanced secretion of adipocyte factors, remain to be elucidated.
Conclusion
Both type 1 and type 2 diabetes are associated with a higher risk of fractures, especially at the level of the hip [2] . Primary care practitioners, endocrinologists, and diabetologists need to be more vigilant in addressing fracture prevention in diabetic patients, especially type 1 diabetic patients and elderly patients with longstanding type 2 diabetes who are at greatest risk. Vitamin D status should be assessed on a yearly basis and vitamin D deficiency must [65] be corrected and routine calcium supplementation instituted . Avoiding medications that increase fall risk or further increase fracture risk might reduce the high morbidity, mortality, and the economic burden associated with bone fractures in diabetic patients.
